Blood immune testing to predict melanoma response to immunotherapy
Part of Cancer, Skin clinical trials.
This study checks how your immune system behaves (through an immune testing process) to see if it can predict how well advanced melanoma will respond to checkpoint inhibitor treatment. It may help doctors choose the right treatment sooner, without guessing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are an adult (major age).
- You have confirmed advanced melanoma that has spread.
- Your cancer status has been measured using RECIST 1.1 criteria.
- You are starting checkpoint inhibitor treatment as your first line (first treatment choice).
- You do NOT have melanoma only in the eyes or mouth/mucous areas.
- You have not received checkpoint inhibitor treatment before.
- You do not have active brain metastases.
- You are not taking medicines that strongly suppress the immune system. (Examples include certain long-term steroids or other immunosuppressants.)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at how melanoma cells “use energy” (tumor metabolism) to understand why immunotherapy can become less effective over time. If you are starting immunotherapy for advanced skin melanoma, the results may help improve future treatments for resistance.
This study is testing a new blood test called IOpener®-Melanoma to see if it can predict which patients with advanced melanoma will respond well to immunotherapy. The goal is to better match treatments to people who will benefit most.
This study looks at immune cells in your blood to find patterns that might show how well a treatment called anti-PD1 immunotherapy works for melanoma. Your participation could help doctors better understand who benefits from this therapy.
This trial studies whether a simple blood test can predict how well your immune system will respond to immunotherapy (such as Keytruda or Opdivo). You may qualify if you have lung cancer (NSCLC) or advanced melanoma and are about to start this type of treatment for the first time.
This trial is testing a simple blood test (liquid biopsy) to track how well melanoma responds to immunotherapy. It might help doctors decide if treatment is working or needs to be changed.
This trial looks at tissue and scan-related markers (“biomarkers”) to better understand how immunotherapy works in people with advanced melanoma. You may receive standard first-line immunotherapy, and your recent scans and health details will help researchers study why some people respond better than others.
Hear when a new Melanoma (Skin) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.